Novamind Inc.

Novamind Inc.

Private Company
Public Company
Subsidiary of
Clinical Immersions
Clinical Trials, R&D

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit

Cedar Psychiatry

One of America’s leading providers of psychedelic medicine
Developing a national clinic network to administer psychedelic medicine pending the FDA approval of MDMA in 2023 and psilocybin in 2025 

5 clinics open, 3 clinics coming soon, September – October 2021

Facilitated over 20,000 clinic visits in 2020, +100% year-over-year 

$1.85M in fiscal Q3 revenue, +43% quarter-over-quarter

Forecasted to increase patient volume from 20,000 clinic visits recorded in 2020 to approximately 65,000 clinic visits in 2021, +225% year-over-year

Planning a multistate clinic footprint in 2021, via organic growth and M&A
Treating people today, positioned for what’s next
Over 7,000 ketamine-assisted therapy sessions delivered since 2016

Over 2,800 Spravato (esketamine) doses administered since 2019

Cedar Psychiatry offers other mental health services including Transcranial Magnetic Stimulation (TMS), cognitive behavioural therapy, medication management and diagnostic evaluations
Cedar Clinical Research
An experienced host of phase I to IV clinical trials and a recognized leader in clinical research focused on psychedelics and mental health

A contract research organization (CRO) facilitating clinical trials on behalf of pharmaceutical companies in addition to leading internal research studies

Novamind’s Chief Medical Officer, Dr. Reid Robinson, is a coordinating investigator of MAPS’ clinical trial examining MDMA-assisted psychotherapy for eating disorders

Developing psychedelic therapy protocols targeting treatment resistant mental illness

Hosted a pivotal ketamine study that led to the FDA-approval of Spravato, the first, fast-acting drug for depression by Janssen Pharmaceuticals

Currently contracted for eight clinical trials

Key research site for Merck & Co.’s phase II clinical trial of MK-1942 for treatment-resistant depression 

Selected as a research site for Bionomics’ phase IIb clinical trial of BNC210 for PTSD

Research also partners include Otsuka, Avanir Pharmaceuticals, the Ketamine Research Foundation, the Center for Change and the University of Texas at Austin